IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences (NASDAQ: IDYA) announced on November 28, 2025 that its Compensation Committee granted non-qualified stock options on November 26, 2025 to a newly hired employee under the 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced on November 28, 2025 that its Compensation Committee granted non-qualified stock options on November 26, 2025 to a newly hired employee under the 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The grant totals 17,600 options with an exercise price of $35.88 per share (equal to the closing Nasdaq price on the grant date). Options carry a 10-year term and vest over four years: 25% on the first anniversary of the vesting commencement date and the remaining 75% in equal monthly installments over the following three years, subject to continued service.

Argus Nov 28 session

-0.72% close to close Open Argus

Details

News Market Reaction – IDYA

On Nov 28, the day this news came out, IDYA closed 0.72% below the previous close.

Data tracked by StockTitan Argus for the Nov 28 session.

Key Figures

Inducement options: 17,600 options Exercise price: $35.88 per share Option term: 10-year term +2 more

Inducement options

17,600 options

Grant to newly hired employee under 2023 Inducement Plan

Exercise price

$35.88 per share

Equal to Nasdaq closing price on Nov 26, 2025 grant date

Option term

10-year term

Non-qualified stock options granted under inducement plan

Initial vesting

25% at 1 year

First anniversary of vesting commencement date

Remaining vesting

75% over 3 years

Equal monthly installments after first anniversary

Historical Context

5 past events · Latest: Dec 10

5 events

1. Dec 10

   IND submission

   24h Move

   -1.3%

   Filed IND for IDE574 targeting Phase 1 monotherapy trial in Q1 2026.

2. Dec 04

   IND clearance

   24h Move

   +4.7%

   FDA IND clearance for IDE034 bispecific ADC with Phase 1 enrollment in Q1 2026.

3. Dec 01

   IND clearance

   24h Move

   -3.7%

   Announced FDA IND clearance for IDE034 enabling Phase 1 trial in solid tumors.

4. Nov 28

   Equity compensation

   24h Move

   -0.7%

   Granted 17,600 stock options to a new hire under 2023 Inducement Plan.

5. Nov 24

   Investor events

   24h Move

   +2.0%

   Announced CEO participation in early December 2025 healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 17,600 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 26, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,600 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $35.88 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302627243.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEAYA (IDYA) announce on November 28, 2025 regarding employee stock options?

IDEAYA announced a grant of 17,600 non-qualified stock options to a newly hired employee, approved November 26, 2025, under the 2023 Inducement Plan.

What is the exercise price and term of the IDYA inducement stock options granted November 26, 2025?

The options have an exercise price of $35.88 per share and a 10-year term.

How do the IDYA inducement options vest and when does vesting begin?

Vesting is over four years: 25% vests on the first anniversary of the vesting commencement date, then the remaining 75% vests in equal monthly installments over the next three years, subject to continued service.

Under what plan and Nasdaq rule were the IDEAYA (IDYA) inducement grants made?

The grant was made under the 2023 Inducement Plan as an inducement material to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Does the $35.88 exercise price reflect IDEAYA's market price on the grant date?

Yes. The exercise price of $35.88 equals IDEAYA's closing price on The Nasdaq Global Select Market on the date of grant.